Drugs / JNJ 10229570-AAA
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01494714 | Aug → Sep 2011 | — | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT01492647 | Aug → Oct 2011 | acne | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01326780 | Mar 2011 → Mar 2012 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ 10229570-AAA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01326780 ↗ |
| Route | Topical | “1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks” NCT01326780 ↗ |